MedTrace Logo

Acetaminophen Biomarkers

NCT01005173 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 253

Last updated 2017-11-24

No results posted yet for this study

Summary

This study is a non-intervention, multicenter study to address biomarkers of acetaminophen toxicity in children. Specifically, the study will examine acetaminophen (APAP) protein adducts and markers of liver injury in the blood samples of hospitalized children and adolescents who are receiving standard doses of acetaminophen, and children and adolescents who are status post acetaminophen overdose. Ultimately, the data generated from this study will be used to establish second generation biomarkers of acetaminophen toxicity, based on specific adduct proteins, which can be used in future risk assessment studies of children receiving acetaminophen.

Conditions

  • Acetaminophen Toxicity

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Arkansas Children's Hospital Research Institute

    lead OTHER

Principal Investigators

  • Laura P James, MD · Arkansas Children's Hospital Research Institute

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01005173 on ClinicalTrials.gov